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In view of the alarming spread of antimicrobial resistance in the absence of new antibiotics, this study aimed
at assessing the availability of potentially useful older antibiotics. A survey was performed in 38 countries
among experts including hospital pharmacists, microbiologists, and infectious disease specialists in Europe,
the United States, Canada, and Australia. An international expert panel selected systemic antibacterial drugs
for their potential to treat infections caused by resistant bacteria or their unique value for specific criteria.
Twenty-two of the 33 selected antibiotics were available in fewer than 20 of 38 countries. Economic motives
were the major cause for discontinuation of marketing of these antibiotics. Fourteen of 33 antibiotics are
potentially active against either resistant Gram-positive or Gram-negative bacteria. Urgent measures are then
needed to ensure better availability of these antibiotics on a global scale.
In the European Union, at least 25 000 persons are es-
timated to die each year from an infection caused by
multidrug-resistant bacteria [1]. In the United States, just
one organism, methicillin-resistant Staphylococcus aureus
(MRSA), kills more Americans every year (approxi-
mately 19 000) than emphysema, human immunodefi-
ciency virus/AIDS, Parkinson’s disease, and homicide
combined [2]. There is a gap between the current
worldwide spread of multiresistant bacteria and the
development of new antimicrobial drugs [1, 3–5]. Few
new antibiotics are in the drug development pipeline; in
particular, recent analyses have shown that few anti-
biotics in development have documented in vitro activity
against antibiotic-resistant Gram-negative bacteria [1, 3].
Furthermore, the arsenal of available antimicrobial drugs
is becoming smaller because older drugs are disappearing
from the market or are temporarily unavailable. The
ESCMID (European Society of Clinical Microbiology
and Infectious Diseases) Study Group for Antibiotic
Policies (ESGAP) performed a review in 2006 which
showed that shortages of narrow-spectrum antibacterial
drugs forced clinicians to use broad-spectrum drugs,
adversely influencing the policies of prudent use [6, 7].
The reasons for shortages and market withdrawals of
older antibiotics are incompletely understood. However,
the lack of profit for drugs in limited market areas (small
countries) and increasing regulatory requirements and
bureaucracy appear to play a role. Several older, poten-
tially useful, sometimes ‘‘forgotten’’ antibiotics are not
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available in many countries, either never having been in-
troduced or having now been withdrawn [8–10]. In view of
the alarming development of resistance in the absence of new
antibiotics, it seemed opportune to collect reliable information on
the availability of currently useful older antibiotics. This study
had 3 objectives: (1) to select systemic antibiotics (Anatomical
Therapeutic Chemical [ATC] code J01) with (potential) activity
on resistant microorganisms and/or having a unique value
for specific criteria and that had at any time been marketed in
Europe, the United States, Canada, and Australia; (2) to assess
the evidence base of efficacy of these antibiotics in infections
caused by current antibiotic-resistant bacteria, or their unique
value; and (3) to make an inventory of these selected antibiotics’
availability in Europe, the United States, Canada, and Australia.
MATERIALS AND METHODS
Selection of Potentially Useful Antibiotics
We reviewed the list of all systemic antibacterials (ATC code J01,
http://www.whocc.no/atc_ddd_publications/guidelines/) [11]
that have been approved for human use by the US Food and Drug
Administration (FDA) and/or the European Medicines Agency
(EMA) and/or in the following countries: Europe (35 countries,
Supplementary Table 1), Canada, and Australia. Exclusion criteria
included (1) antibiotics currently marketed in all countries of
interest; (2) antituberculous, antifungal, antiparasitic, and antivi-
ral drugs; and (3) topical- or inhaled-only antibacterials. Newly
approved drugs, such as telavancin, ceftaroline, and fidaxomicin,
were beyond the scope of our review.
Six experts (2 from Europe, 2 from the United States, and
2 from Australia) with clinical/microbiological expertise in
the field were chosen as assessors. Five of them were authors
of a leading reference textbook on antimicrobial drugs [12].
All authors selected the antibiotics for their potential value
against current resistant bacteria and/or for their unique
value for specific criteria, based on the textbook (Kucers’)
[12] and their own experience.
Assessment of the Potential of These Antibiotics Against
Currently Resistant Bacteria and of Their Unique Value
PubMed was searched for literature relevant to the selected
antibiotics, published until October 2010 inclusive. Based on
this literature review and the expert panel advice, the potential
activity of the selected antibiotics was assessed against a selection
of resistant bacteria.
For assessment of the value of the antibiotics, the method
described in the ‘‘European Centre for Disease Prevention and
Control/European Medicines Agency joint technical report
2009–the bacterial challenge: time to react’’ was applied [1, 3].
The following antibiotic-resistant bacteria were selected because
they frequently cause bloodstream infections and because the
associated antibiotic resistance trait is, in most cases, a marker
for multiple resistance to antibiotics: MRSA; vancomycin-
intermediate S. aureus (VISA) and vancomycin-resistant S. aureus;
vancomycin-resistant enterococci (VRE; eg, Enterococcus faecium);
penicillin-resistant Streptococcus pneumoniae; third-generation
cephalosporin–resistant Enterobacteriaceae (eg, Escherichia coli,
Klebsiella pneumoniae); carbapenem-resistant Enterobacteriaceae
(eg, K. pneumoniae); and carbapenem-resistant nonfermentative
Gram-negative bacteria (eg, Pseudomonas aeruginosa).
The selected agents were assessed for their antibacterial ac-
tivity against the selected bacteria based on actual data available
in the reference textbook [12] and/or the literature. In the
absence of available in vitro data, the expert panel also took
into account reasonable assumptions of the activity of some
agents based on the properties of similar agents (ie, of the same
class or with a common mechanism of action) to construct
a ‘‘best-case scenario.’’
In vitro activity of each agent against the selected bacteria was
assigned based on the following approaches:
d Actual data on in vitro activity were reviewed whenever
available. If actual data on in vitro activity were not
reported for an agent against any of the selected
pathogens, assumptions were made regarding likely
activity based on the properties of the antibiotic class or
of the mechanism of action involved.
d The assessment of in vitro activity disregarded any known
potential for cross-resistance and coresistance.
d Although in vitro activity alone cannot predict in vivo
efficacy, it was decided not to take into account any
available pharmacokinetic data or pharmacokinetics/
pharmacodynamics (PK/PD) analyses when scoring the
antibacterial activity of agents because the amount of
data available was very variable. However, if there was
already information available on nonclinical or clinical
efficacy, these data were factored into the assessment.
d The assignment of in vitro activity, which took into
account available data together with assumptions based
on class properties or mechanisms of action as well as the
route of administration, took the most optimistic view of
what the agent might be able to achieve and represents
a best-case scenario.
The unique value of each of these antibiotics, according to specific
criteria (eg, oxacillin allows a narrow-spectrum treatment of
methicillin-susceptible S. aureus [MSSA]), was also determined,
based on the comments of the expert panel. Criteria included
(1) microbiological criteria: spectrum, mechanism of action;
(2) pharmacokinetic criteria; and (3) clinical criteria: ‘‘niche’’
antibiotic (unique value for specific pathogens or indications), last
available molecule of its class, and absence of alternative.
Each antibiotic was randomly assigned to 2 experts for as-
sessment, except for those antibiotics where 1 of the experts was
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the author of the Kucers’ chapter, in which case the antibiotic
was assigned to the author. If the 2 assessments were concor-
dant, the evaluation was final. In case of nonagreement between
the 2 experts, the antibiotic was evaluated by all 6 experts to
reach a consensus.
Survey on the Availability of Selected Antibiotics in Europe, the
United States, Canada, and Australia
Contacts (belonging to personal networks of the authors
and/or being members of ESGAP and/or ESCMID PK/PD of
Anti-infectives Study Group) in the selected countries were
approached by e-mail in the northern hemisphere in Autumn
2010–Winter 2011 to report on the availability of the selected
antibiotics in their country. The data collected were entered
in a Microsoft Excel spreadsheet. These data were compared
by the lead author (C. P.) with information on the national
drug agencies’ Web sites (Supplementary Table 2) and the
Martindale pharmacopoeia [13]. Whenever possible, a distinc-
tion was made between antibiotics easily available through
usual marketing processes and antibiotics available via a special
regulatory scheme. The availability of inhalational formulations
and reasons for withdrawal or abbreviated (,1 year) marketing
of the antibiotic were also explored.
RESULTS
Thirty-three valuable antibiotics were selected (Figure 1). Many
had multiple features considered to be of value.
Assessment of the Potential of Selected Antibiotics Against
Resistant Bacteria and of Their Unique Value
Thirty-one of 33 antibiotics were found to be either active against
resistant bacteria or having unique value after the literature re-
view; cefpodoxime and ceftibuten were included in the survey
but, upon inspection of their current susceptibility profiles,
did not meet any of the criteria established for future utility.
A summary of the results is presented in Tables 1 and 2
(a more detailed assessment by antibiotic is available as
Supplementary Appendix 1). Fourteen of 33 antibiotics were
active against resistant Gram-positive bacteria (MRSA, VISA,
penicillin-resistant pneumococci, or VRE). Fourteen of 33 an-
tibiotics were active against resistant Gram-negative bacteria
(third-generation cephalosporin–resistant Enterobacteriaceae,
carbapenem-resistant Enterobacteriaceae, or non-fermentative
bacteria). Twenty-two antibiotics were considered to have a
unique value, including 9 antibiotics having a unique value
for treating specific pathogens or for specific indications
Figure 1. Availability of the selected 33 antibiotics in 38 countries (Europe, United States, Canada, and Australia), displayed by antibiotic.
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(5 antistaphylococcal penicillins for MSSA infections, peni-
cillin G for syphilis, spectinomycin for gonorrhea, penicillin V,
and temocillin).
Availability of These Antibiotics in Europe, the United States,
Canada, and Australia
The availability data obtained for the United States, Canada,
Australia, and 35 European countries are shown in Figure 1 and
Supplementary Figure 1. Detailed information is available in
Supplementary Appendix 2. We had no data for 1 European
country, and data regarding 2 other European countries were
collected using national Web sites, in the absence of national
contacts. Surprisingly, the number and the mode of availability
(marketed or via a special system) differed considerably from one
country to another. Twenty-two of the 33 selected antibiotics were
marketed in fewer than 20 countries.
Table 1. Selected Systemic Antibacterial Agents and In Vitro/In Vivo Activity Against Selected Resistant Bacteria Based on Actual Data
Agent
Gram-positive bacteria Gram-negative bacteria
MRSA VISA/VRSA PRSP VRE
3rd gen.
cep. R ENB
Carb.
R ENB
Carb. R
NF GNB
Antistaphylococcal penicillins: nafcillin and isoxazolyl
penicillins: oxacillin, cloxacillin, dicloxacillin, and
flucloxacillin
Aztreonam ha ha
Cefepime n hb
Cefoperazone-sulbactam n n
Cefoxitin hc
Cefpodoxime and ceftibuten
Chloramphenicol and thiamphenicol n n h n h h
Colistin n n n
Ertapenem h h
Fosfomycin n n n n n h
Fusidic acid n n n
Mecillinam and pivmecillinam h
Methenamined n n n n n n
Nitrofurantoin n n n
Penicillin V and penicillin G
Pristinamycin n n h
Quinupristin-dalfopristin n n n ne
Spectinomycin h
Teicoplanin n n nf
Temocillin n n
Tobramycin h h h n n n
Trimethoprim n n n
Summary of the potential activity of the antibacterial agents against selected resistant bacteria
n 9 4 7 7 8 5 3
h 2 1 2 2 5 1 3
Total 11 5 9 9 13 6 6
Activity: n indicates usually active andh indicates sometimes active. The activity of each drug is variable, according to the clinical situation (eg, bacterial species for
Gram-negative bacteria, mechanism of resistance, site of infection, pharmacokinetics/pharmacodynamics indices). Data presented in the table represent the best-
case scenario, are mainly level 3 quality of evidence, and are not treatment guidelines. A more in-depth analysis is available in Supplementary Appendix 1.
Abbreviations: Carb. R ENB, carbapenem-resistant Enterobacteriaceae; Carb. R NF GNB, carbapenem-resistant nonfermentative Gram-negative bacteria;
ESBL, extended-spectrum b-lactamase; 3rd gen. cep. R ENB, third-generation cephalosporin–resistant Enterobacteriaceae; MIC, minimum inhibitory concentration;
MRSA, methicillin-resistant Staphylococcus aureus; PRSP, penicillin-resistant Streptococcus pneumoniae (MIC.2 mg/L); VISA, vancomycin-intermediate S.
aureus; VRSA, vancomycin-resistant S. aureus; VRE, vancomycin-resistant enterococci.
a Active only if a metallo-b-lactamase is produced in the absence of overexpressed AmpC or in the absence of an ESBL.
b Active on AmpC chromosomally mediated b-lactamases; active on ESBLs only if MIC ,4 mg/L.
c Inactive on some Enterobacteriaceae such as Enterobacter species, Citrobacter species, Serratia species, and Providencia species.
d Potentially active against resistant bacteria because it is converted to formaldehyde in acidic urine and therefore has broad-spectrum ‘‘disinfectant’’ properties
(except on urease-producing strains), but lacks evidence.
e Active on Enterococcus faecium.
f Active except on VanA type.
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Economic motives are the major cause for discontinuation of
marketing of these antibiotics, for example, penicillin G and
cloxacillin in Croatia (not profitable to the local industry) or
penicillin V and oxacillin in Latvia (for more information, see
Supplementary Appendix 2). In Switzerland, cefoxitin and az-
treonam were withdrawn due to small volume sales. In Turkey,
Table 2. Unique Value of the Selected Antibacterial Agents, Using Microbiological, Pharmacokinetic, and Clinical Criteria
Criteria The 22 Antibiotics Having Unique Value for 1 or Several Criteria
Microbiological criteria: spectrum, 14 antibiotics - Antistaphylococcal penicillins (nafcillin and isoxazolyl penicillins:
oxacillin, cloxacillin, dicloxacillin, and flucloxacillin): narrow-spectrum
drug to treat MSSA infections
- Cefoxitin: infections due to Mycobacterium abscessus, Mycobacterium
fortuitum, and Mycobacterium chelonae
- Chloramphenicol and thiamphenicol: gonococci, broad-spectrum
drug (eg, Rickettsia, Stenotrophomonas maltophilia)
- Penicillin G: Treponema pallidum
- Quinupristin-dalfopristin: Enterococcus faecium
- Spectinomycin: Neisseria gonorrhoeae
- Teicoplanin: E. faecium with vanB/C resistance and
amoxicillin-resistant Enterococcus gallinarum/casseliflavus
- Temocillin: Burkholderia cepacia
- Tobramycin: Pseudomonas aeruginosa
Microbiological criteria: mechanism of action,
6 antibiotics
- Chloramphenicol and thiamphenicol
- Colistin
- Fosfomycin
- Fusidic acid
- Nitrofurantoin
PK criteria, 5 antibiotics - Chloramphenicol and thiamphenicol: excellent diffusion into central
nervous system and eye
- Ertapenem: once-daily parenteral (IV/IM) administration; convenient
as OPAT
- Fosfomycin oral formulations: 1 dose only for uncomplicated cystitis
- IV fosfomycin: excellent diffusion into central nervous system and eye
- Teicoplanin: OPAT possible
Clinical criteria: ‘‘niche’’ agent (unique value
for specific pathogens or indications), 9 antibiotics
- Antistaphylococcal penicillins (nafcillin and isoxazolyl penicillins:
oxacillin, cloxacillin, dicloxacillin, and flucloxacillin): ‘‘niche’’ agent for
MSSA infections
- Penicillin V: rheumatic fever and postsplenectomy prophylaxis regimens
- Penicillin G: T. pallidum
- Long-acting forms of penicillin G: syphilis and chemoprophylaxis
of rheumatic fever
- Spectinomycin: ‘‘niche’’ agent for gonorrhoea
- Temocillin: ‘‘niche’’ agent for B. cepacia infections (EMA/FDA: orphan
status in cystic fibrosis)
Clinical criteria: last (only) available antibiotic of
its class, 8 antibiotics
- Aztreonam (only monobactam): useful in case of b-lactam allergy
because cross-reactivity with penicillins and cephalosporins is rare
- Chloramphenicol and thiamphenicol
- Colistin (only available polymyxin E)
- Fosfomycin
- Fusidic acid
- Methenamine
- Spectinomycin
Clinical criteria: absence of alternative, 2 antibiotics - Colistin: absence of alternative for some multiresistant Gram-negative strains
- Quinupristin-dalfopristin: amoxicillin-, daptomycin-, and vancomycin-resistant
E. faecium
Abbreviations: EMA, European Medicines Agency; FDA, US Food and Drug Administration; IV, intravenous; IM, intramuscular; MSSA, methicillin-susceptible
Staphylococcus aureus; OPAT, Outpatient Parenteral Antibiotic Therapy; PK, pharmacokinetics.
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colistin was recently approved, produced, and marketed by
a local company, in response to the urgent need following the
countrywide rise in multidrug-resistant Gram-negative in-
fections.
DISCUSSION
The major finding of this inventory was that many potentially
useful antibiotics, usually low cost andmarketed as generics, and
with a long history of tolerability and safety data, are not
available in many countries. This is a worrisome situation, given
the current worldwide bacterial resistance crisis. Urgent meas-
ures are needed to ensure a better availability of these antibiotics
on a global scale. It is also worrisome that obtaining a reliable
overview on the availability of these antibiotics in the selected
Western countries was quite difficult. We also noted discrepancies
between the data sent by the national contacts, many of whom
were senior specialists in the field, and the data available on the
national drug agencies’ Web sites and/or in the Martindale drug
reference, which illustrates the lack of transparency and in-
formation on drug availability. Moreover, in many different
countries, some antibiotics are available through special and
sometimes complicated regulatory systems, usually delaying the
delivery of the drug, at the price of time-consuming paperwork.
Temocillin and mecillinam could be useful for extended-
spectrum b-lactamase–producing organisms (but only if there is
a low minimal inhibitory concentration for mecillinam and low
inoculum); fosfomycin and colistin may also be used to treat
infections caused by carbapenem-resistant Gram-negative bacilli
(Table 1). These are agents that, in the opinion of the authors,
hold the greatest promise of utility worldwide for managing in-
fections that result from many currently resistant Gram-negative
organisms. However, they were available in only 2, 2, 5, and 25
countries, respectively.
In half of the cases, neither PK/PD data nor clinical data
were available for drugs known to be active in vitro (Sup-
plementary Appendix 1) [14]. Studies on PK/PD could justify
greater availability of those products with advantageous PK/PD
characteristics. In particular, more data on animal models and
clinical studies are needed; in vitro surveillance data on these
drugs are lacking in the available networks such as the European
Antimicrobial Resistance Surveillance Network and SENTRY;
clinical registers are nonexistent. We hope that our inventory can
contribute to the renewed interest of the producers to market
their products in the respective countries.
In view of our results, we would recommend that treating
physicians consider the forgotten antibiotics on our list for
treatment of resistant pathogens. However, use of these drugs
should be based on susceptibility testing provided that standard-
ized susceptibility testing and interpretive criteria are available
(from the Clinical and Laboratory Standards Institute or the
European Committee on Antimicrobial Susceptibility Testing);
not all resistant species may respond to each of the drugs as
predicted in the tables. Our assessment was based on a best-case
scenario and therefore does not represent treatment guidelines.
Companies should give full transparency on the marketing,
distribution, and dispensing of medicines in all countries, and
these data must be easily available. Many of the older antibiotics
are now only produced by pharmaceutical industries in de-
veloping nations, which may further impede the access to these
drugs, because there may be a lack of influence of regulatory
bodies in Europe and elsewhere. In such cases, the EMA and
similar regulators in other regions should establish formal con-
tact to enhance the availability of these antibiotics. In case of
withdrawal of a drug in an individual country because of eco-
nomic reasons, all possible efforts should be made to guarantee
the availability in case of urgent medical need. In addition, the
drug agencies should inform the medical community before
withdrawal of the drug in order for the latter to possibly respond
and perhaps prevent the withdrawal. There is a role for drug
agencies (such as the EMA and FDA) in adapting regulations
accordingly. In our opinion, policy makers are well advised to
guarantee the availability of older and generic antibiotics and
other drugs that are essential for medical care, beyond market-
driven agendas. Reduction of the market registration fees for
such needed antibiotics might be one method to relieve the costs
for the pharmaceutical companies.
An equally challenging problem for manufacturers and po-
tential prescribers is obtaining registration of older antibiotics
that have never been registered before in that country or region.
In many cases, the data available do not reach modern regula-
tory requirements and standards. For example, the introduction
of fusidic acid into the US market has required a small US-based
pharmaceutical company to undertake extensive in vitro, ani-
mal, and clinical studies to comply with the FDA requirements
for new agents [15]. This process is ongoing, costly, and will take
years, and it is occurring in the face of extensive clinical expe-
rience with the agent in several countries over the course of
nearly 40 years. To expedite the process of newly registering
older antibiotics, it is a matter of urgency that regulatory
agencies worldwide develop new, perhaps less burdensome
procedures so that these agents can be used globally in a timely
manner. Better international harmonization is certainly needed
for the regulatory agencies to attain all of these objectives.
Our study is strengthened by the use of an already published
method, thus allowing us to compare data on older antibiotics
with data on new antibiotics that are still in development [3].
Due to the chosen method, our inventory was limited to selected
countries/regions. However, it would be interesting to extend
the inventory to other regions such as Asia, South America, and
Africa, depending on the complexity and diversity of their reg-
ulatory environments.
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In conclusion, we have identified 31 particularly useful anti-
biotics that are available in a limited number of countries sur-
veyed. These antibiotics will be forgotten by new generations of
clinicians, unless they are reminded of their potential utility, thus
limiting the best medical practice in that country. Urgentmeasures
are now needed to ensure a better availability of these antibiotics
on a global scale and to conduct additional research regarding the
benefit of these antibiotics in current clinical infections.
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